NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
SAN FRANCISCO, Oct. 17, 2011 - Sutro's Chief Scientific Officer, Trevor Hallam, Ph.D., to Highlight Company's Technology Platform for the Highly Specific Design and Manufacturing of Novel Protein Therapeutics Sutro Biopharma, a biopharmaceutical company developing...
Study Shows Sutro Biopharma’s Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals Results Published in Biotechnology and Bioengineering Demonstrate that Cell-Free Production of a Biologically Active Human Cytokine Can be Scaled-up to Commercial Manufacturing Levels Study Featured in Journal’s Spotlight Section.
SAN FRANCISCO, May 19, 2011 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that a study published in the July issue of Biotechnology and...
Microscale to Manufacturing Scale-up of Cell-Free Cytokine Production: A New Approach for Shortening Protein Production Development Timelines
James F. Zawada, Gang Yin, Alexander R. Steiner, Junhao Yang, Alpana Naresh, Sushmita M. Roy, Daniel S. Gold, Henry G. Heinsohn, Christopher J. Murray, Microscale to Manufacturing Scale-up of Cell-Free Cytokine Production—A New Approach for Shortening Protein...
Microscale to Manufacturing Scale-up of Cell-Free Cytokine Production: A New Approach for Shortening Protein Production Development Timelines
PHARMACEUTICAL TECHNOLOGY Volume 35, pp. s8-s11 Industrializing Design, Development, and Manufacturing of Therapeutic Proteins By: Trevor J. Hallam, Christopher J. Murray.
“Unnatural Selection”
BioCentury, The Bernstein Report on BioBusiness January 10, 2011 issue article, "Unnatural Selection" in the Tools & Techniques section by BioCentury Senior Editor, Ms. Susan Schaeffer. Read More
Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics. Company’s First Major Collaboration Validates Potential of Biochemical Protein Synthesis Technology Platform.
San Francisco, CA Jan. 7, 2011 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company has entered into a multi-year collaboration with Pfizer for...
Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer Appointment Reflects Biopharmaceutical Company’s Commitment to the Development of Novel and Biosuperior Protein Therapeutics
San Francisco, CA Dec. 8, 2010 - Sutro Biopharma, a biopharmaceutical company developing both novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has appointed Trevor Hallam, Ph.D., as chief scientific officer...
A Robust, Rapid and Scalable Cell Free Expression System for the Production and Engineering of Fab Antibodies
Garces, Eudean et. al., A robust, rapid and scalable cell free expression system for the production and engineering of Fab antibodies. Presented at the IBC 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Convention, San Diego, CA....
Sutro Biopharma Secures $36.5 Million in Series C Financing
South San Francisco, CA Nov. 17, 2010 - Sutro Biopharma today announced that the company has secured $36.5 million in Series C financing. This financing will support the company's ongoing development of novel biotherapeutics with superior pharmaceutical properties and...
Translation Fidelity Rate Determination in a Cell-Free Protein Synthesis System using LC-MS
Heibeck, Tyler H., et. al., Translation Fidelity Rate Determination in a Cell-Free Protein Synthesis System using LC-MS. 58th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics,Salt Lake City, UT. Read More